UGISense AG secures new financing

21-Jun-2018 - Germany

Following the seed financing round in 2016, UGISense AG has again been able to successfully complete a funding round.

In addition to all founding investors (experienced business angels in the field of biotechnology and the Lead Discovery Center Dortmund), SeedCapital II KG from Dortmund as well as the experienced business angel Dr. Uwe Jacob (Westend-Innovation), and healthcare specialist Samuel Stursberg could be convinced of the potential of UGISense AG for this funding round. After the investment has been completed, the headquarters of the company will be transferred from Munich to Dortmund.

The capital enables UGISense to fuel the development and expansion of their proprietary antisense technology (Ugimers™) at the new site. The main goal is to document the broad applicability of the Ugimers™ in different cooperation projects with LDC, but also with partners from the industry and academia and to develop compounds for the corresponding targets. Current projects include areas such as oncology, metabolic diseases as well as muscular dystrophies.

“We are very happy that, in addition to all of the seed investors, we have also been able to fill new investors with enthusiasm for our technology”, say Dr. Birgit Werner and Dr. Thomas Lindhorst, the members of the executive board. “The fresh capital enables us to further distinguish the superiority of the ugimer technology compared to other antisense technologies and to prove the same by means of an extensive pool of data.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.